Engagement of TLR signaling as adjuvant: Towards smarter vaccine and beyond

Vaccine

Volumn 26, Issue 52, 2008, Pages 6777-6783

  Lahiri, Amit ^a   Das, Priyanka ^a   Chakravortty, Dipshikha ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Adjuvant; Antigen presentation; CD4 T cell response; CD8 T cell response; Cytokine; Immune memory; Toll like receptor; Vaccination

Indexed keywords

ADJUVANT; AGATOLIMOD; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CYTOKINE; DNA; DOUBLE STRANDED RNA; FLAGELLIN; GAG PROTEIN; IMIQUIMOD; INTERLEUKIN 1BETA CONVERTING ENZYME; LIPOPEPTIDE; LIPOPOLYSACCHARIDE; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELAN A; NEURONAL APOPTOSIS INHIBITORY PROTEIN; OUTER MEMBRANE PROTEIN; OUTER SURFACE PROTEIN A; PEPTIDOGLYCAN; PHOSPHORYL LIPID A; POLYINOSINIC POLYCYTIDYLIC ACID; RESIQUIMOD; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST; UNINDEXED DRUG; VACCINE;

ANTIGEN PRESENTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CROSS PRESENTATION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN-PRESENTING CELLS; HUMANS; IMMUNOLOGIC MEMORY; PHAGOCYTOSIS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; VACCINES;

EID: 56649108016     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.045     Document Type: Review

References (83)

1. Andre F.E. Vaccinology: past achievements, present roadblocks and future promises. Vaccine 21 January 30 (7-8) (2003) 593-595
2. Esser M.T., Marchese R.D., Kierstead L.S., Tussey L.G., Wang F., Chirmule N., et al. Memory T cells and vaccines. Vaccine 21 January 17 (5-6) (2003) 419-430
3. Alving C.R. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 20 May 31 (Suppl. 3) (2002) S56-S64
4. O'Hagan D.T., and Valiante N.M. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2 September (9) (2003) 727-735
5. Myers K.R., Beining P., Betts M., Snippe H., Inman J., and Golding B. Monophosphoryl lipid A behaves as a T-cell-independent type 1 carrier for hapten-specific antibody responses in mice. Infect Immun 63 January (1) (1995) 168-174
6. Ulrich J.T., and Myers K.R. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol 6 (1995) 495-524
7. Verthelyi D., Kenney R.T., Seder R.A., Gam A.A., Friedag B., and Klinman D.M. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol 168 February 15 (4) (2002) 1659-1663
8. Klinman D.M. Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol 25 May-August (3-4) (2006) 135-154
9. Klinman D.M., Xie H., Little S.F., Currie D., and Ivins B.E. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine 22 July 29 (21-22) (2004) 2881-2886
10. Zimmermann S., Dalpke A., and Heeg K. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections. Int J Med Microbiol 298 January (1-2) (2008) 39-44
11. Takeda K., Kaisho T., and Akira S. Toll-like receptors. Annu Rev Immunol 21 (2003) 335-376
12. Akira S., and Takeda K. Toll-like receptor signalling. Nat Rev Immunol 4 July (7) (2004) 499-511
13. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 October (10) (2004) 987-995
14. van Duin D., Medzhitov R., and Shaw A.C. Triggering TLR signaling in vaccination. Trends Immunol 27 January (1) (2006) 49-55
15. Kaisho T., and Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 1589 February 13 (1) (2002) 1-13
16. Greenberg S., and Grinstein S. Phagocytosis and innate immunity. Curr Opin Immunol 14 February (1) (2002) 136-145
17. Blander J.M. Coupling Toll-like receptor signaling with phagocytosis: potentiation of antigen presentation. Trends Immunol 28 January (1) (2007) 19-25
18. Blander J.M., and Medzhitov R. Regulation of phagosome maturation by signals from toll-like receptors. Science 304 May 14 (5673) (2004) 1014-1018
19. Yates R.M., and Russell D.G. Phagosome maturation proceeds independently of stimulation of toll-like receptors 2 and 4. Immunity 23 October (4) (2005) 409-417
20. Edwards A.D., Manickasingham S.P., Sporri R., Diebold S.S., Schulz O., Sher A., et al. Microbial recognition via Toll-like receptor-dependent and -independent pathways determines the cytokine response of murine dendritic cell subsets to CD40 triggering. J Immunol 169 October 1 (7) (2002) 3652-3660
21. Yarovinsky F., Zhang D., Andersen J.F., Bannenberg G.L., Serhan C.N., Hayden M.S., et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science 308 June 10 (5728) (2005) 1626-1629
22. Diehl L., den Boer A.T., Schoenberger S.P., van der Voort E.I., Schumacher T.N., Melief C.J., et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 5 July (7) (1999) 774-779
23. Ahonen C.L., Doxsee C.L., McGurran S.M., Riter T.R., Wade W.F., Barth R.J., et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 199 March 15 (6) (2004) 775-784
24. Harris T.H., Mansfield J.M., and Paulnock D.M. CpG oligodeoxynucleotide treatment enhances innate resistance and acquired immunity to African trypanosomes. Infect Immun 75 May (5) (2007) 2366-2373
25. Wang J.P., Hayashi T., Datta S.K., Kornbluth R.S., Raz E., and Guiney D.G. CpG oligonucleotides partially inhibit growth of Mycobacterium tuberculosis, but not Salmonella or Listeria, in human monocyte-derived macrophages. FEMS Immunol Med Microbiol 45 August 1 (2) (2005) 303-310
26. Sanchez-Campillo M., Chicano A., Torio A., Martin-Orozco E., Gamiz P., Hernandez-Caselles T., et al. Implication of CpG-ODN and reactive oxygen species in the inhibition of intracellular growth of Salmonella typhimurium in hepatocytes. Microbes Infect 6 July (9) (2004) 813-820
27. Ito S., Ishii K.J., Gursel M., Shirotra H., Ihata A., and Klinman D.M. CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection. J Immunol 174 January 15 (2) (2005) 777-782
28. Babiuk S., Mookherjee N., Pontarollo R., Griebel P., van Drunen Littel-van den Hurk S., Hecker R., et al. TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine. Immunology 113 September (1) (2004) 114-120
29. den Haan J.M., Lehar S.M., and Bevan M.J. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 192 December 18 (12) (2000) 1685-1696
30. Datta S.K., Redecke V., Prilliman K.R., Takabayashi K., Corr M., Tallant T., et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol 170 April 15 (8) (2003) 4102-4110
31. Zaks K., Jordan M., Guth A., Sellins K., Kedl R., Izzo A., et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 176 June 15 (12) (2006) 7335-7345
32. Heit A., Huster K.M., Schmitz F., Schiemann M., Busch D.H., and Wagner H. CpG-DNA aided cross-priming by cross-presenting B cells. J Immunol 172 February 1 (3) (2004) 1501-1507
33. Schulz O., Diebold S.S., Chen M., Naslund T.I., Nolte M.A., Alexopoulou L., et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433 February 24 (7028) (2005) 887-892
34. Mutwiri G.K., Nichani A.K., Babiuk S., and Babiuk L.A. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J Control Release 97 May 31 (1) (2004) 1-17
35. Schlosser E., Mueller M., Fischer S., Basta S., Busch D.H., Gander B., et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 26 March 20 (13) (2008) 1626-1637
36. Gelman A.E., Zhang J., Choi Y., and Turka L.A. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol 172 May 15 (10) (2004) 6065-6073
37. Zheng Y., Vig M., Lyons J., Van Parijs L., and Beg A.A. Combined deficiency of p50 and cRel in CD4+ T cells reveals an essential requirement for nuclear factor kappaB in regulating mature T cell survival and in vivo function. J Exp Med 197 April 7 (7) (2003) 861-874
38. Hervas-Stubbs S., Olivier A., Boisgerault F., Thieblemont N., and Leclerc C. TLR3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help. Blood 109 June 15 (12) (2007) 5318-5326
39. Wille-Reece U., Flynn B.J., Lore K., Koup R.A., Miles A.P., Saul A., et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 203 May 15 (5) (2006) 1249-1258
40. Takeda K., Takeuchi O., and Akira S. Recognition of lipopeptides by Toll-like receptors. J Endotoxin Res 8 6 (2002) 459-463
41. Cluff C.W., Baldridge J.R., Stover A.G., Evans J.T., Johnson D.A., Lacy M.J., et al. Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect Immun 73 May (5) (2005) 3044-3052
42. Ishizaka S.T., and Hawkins L.D. E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant. Expert Rev Vaccines 6 October (5) (2007) 773-784
43. Cohen N., Stolarsky-Bennun M., Amir-Kroll H., Margalit R., Nussbaum G., Cohen-Sfady M., et al. Pneumococcal capsular polysaccharide is immunogenic when present on the surface of macrophages and dendritic cells: TLR4 signaling induced by a conjugate vaccine or by lipopolysaccharide is conducive. J Immunol 180 February 15 (4) (2008) 2409-2418
44. Thomas V., and Fikrig E. The Lyme disease vaccine takes its toll. Vector Borne Zoonotic Dis 2 Winter (4) (2002) 217-222
45. Luke C.J., Huebner R.C., Kasmiersky V., and Barbour A.G. Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi. Vaccine 15 Apr-May (6-7) (1997) 739-746
46. Alexopoulou L., Thomas V., Schnare M., Lobet Y., Anguita J., Schoen R.T., et al. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat Med 8 August (8) (2002) 878-884
47. Yoder A., Wang X., Ma Y., Philipp M.T., Heilbrun M., Weis J.H., et al. Tripalmitoyl-S-glyceryl-cysteine-dependent OspA vaccination of toll-like receptor 2-deficient mice results in effective protection from Borrelia burgdorferi challenge. Infect Immun 71 July (7) (2003) 3894-3900
48. Tsuji S., Matsumoto M., Takeuchi O., Akira S., Azuma I., Hayashi A., et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infect Immun 68 December (12) (2000) 6883-6890
49. Latz E., Franko J., Golenbock D.T., and Schreiber J.R. Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity. J Immunol 172 February 15 (4) (2004) 2431-2438
50. Huleatt J.W., Jacobs A.R., Tang J., Desai P., Kopp E.B., Huang Y., et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25 January 8 (4) (2007) 763-775
51. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26 January 10 (2) (2008) 201-214
52. Robinson R.A., DeVita V.T., Levy H.B., Baron S., Hubbard S.P., and Levine A.S. A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patients with leukemia or solid tumors. J Natl Cancer Inst 57 September (3) (1976) 599-602
53. Adams M., Navabi H., Jasani B., Man S., Fiander A., Evans A.S., et al. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). Vaccine 21 January 30 (7-8) (2003) 787-790
54. Salem M.L., El-Naggar S.A., Kadima A., Gillanders W.E., and Cole D.J. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine 24 June 12 (24) (2006) 5119-5132
55. Asahi-Ozaki Y., Itamura S., Ichinohe T., Strong P., Tamura S., Takahashi H., et al. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect 8 October (12-13) (2006) 2706-2714
56. Trumpfheller C., Caskey M., Nchinda G., Longhi M.P., Mizenina O., Huang Y., et al. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci U S A 105 February 19 (7) (2008) 2574-2579
57. Fransen F., Boog C.J., van Putten J.P., and van der Ley P. Agonists of Toll-like receptors 3, 4, 7 and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B. Infect Immun 75 December (12) (2007) 5939-5946
58. Johnston D., Zaidi B., and Bystryn J.C. TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines. Cancer Immunol Immunother 56 August (8) (2007) 1133-1141
59. Wille-Reece U., Flynn B.J., Lore K., Koup R.A., Kedl R.M., Mattapallil J.J., et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci U S A 102 October 18 (42) (2005) 15190-15194
60. Wagner H. The immunobiology of the TLR9 subfamily. Trends Immunol 25 July (7) (2004) 381-386
61. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5 June (6) (2006) 471-484
62. Waag D.M., McCluskie M.J., Zhang N., and Krieg A.M. A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei. Infect Immun 74 March (3) (2006) 1944-1948
63. Krieg A.M. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27 January 7 (2) (2008) 161-167
64. Ma R., Du J.L., Huang J., and Wu C.Y. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination. Biochem Biophys Res Commun 361 September 21 (2) (2007) 537-542
65. Kwissa M., Amara R.R., Robinson H.L., Moss B., Alkan S., Jabbar A., et al. Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J Exp Med 204 October 29 (11) (2007) 2733-2746
66. Zwiorek K., Bourquin C., Battiany J., Winter G., Endres S., Hartmann G., et al. Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm Res 25 March (3) (2008) 551-562
67. Speiser D.E., Lienard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115 March (3) (2005) 739-746
68. Ishii K.J., and Akira S. Toll or toll-free adjuvant path toward the optimal vaccine development. J Clin Immunol 27 July (4) (2007) 363-371
69. Fritz J.H., Ferrero R.L., Philpott D.J., and Girardin S.E. Nod-like proteins in immunity, inflammation and disease. Nat Immunol 7 December (12) (2006) 1250-1257
70. Shaw M.H., Reimer T., Kim Y.G., and Nunez G. NOD-like receptors (NLRs): bona fide intracellular microbial sensors. Curr Opin Immunol 20 Aug (4) (2008) 377-382
71. Opitz B., Puschel A., Schmeck B., Hocke A.C., Rosseau S., Hammerschmidt S., et al. Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae. J Biol Chem 279 August 27 (35) (2004) 36426-36432
72. Buchholz K.R., and Stephens R.S. The cytosolic pattern recognition receptor NOD1 induces inflammatory interleukin-8 during Chlamydia trachomatis infection. Infect Immun 76 July (7) (2008) 3150-3155
73. Fremond C.M., Yeremeev V., Nicolle D.M., Jacobs M., Quesniaux V.F., and Ryffel B. Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88. J Clin Invest 114 December (12) (2004) 1790-1799
74. Molofsky A.B., Byrne B.G., Whitfield N.N., Madigan C.A., Fuse E.T., Tateda K., et al. Cytosolic recognition of flagellin by mouse macrophages restricts Legionella pneumophila infection. J Exp Med 203 April 17 (4) (2006) 1093-1104
75. Zamboni D.S., Kobayashi K.S., Kohlsdorf T., Ogura Y., Long E.M., Vance R.E., et al. The Birc1e cytosolic pattern-recognition receptor contributes to the detection and control of Legionella pneumophila infection. Nat Immunol 7 March (3) (2006) 318-325
76. Roy C.R., and Zamboni D.S. Cytosolic detection of flagellin: a deadly twist. Nat Immunol 7 June (6) (2006) 549-551
77. Miao E.A., Alpuche-Aranda C.M., Dors M., Clark A.E., Bader M.W., Miller S.I., et al. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat Immunol 7 June (6) (2006) 569-575
78. Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5 July (7) (2004) 730-737
79. Yoneyama M., Kikuchi M., Matsumoto K., Imaizumi T., Miyagishi M., Taira K., et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 175 September 1 (5) (2005) 2851-2858
80. Gitlin L., Barchet W., Gilfillan S., Cella M., Beutler B., Flavell R.A., et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A 103 May 30 (22) (2006) 8459-8464
81. Kato H., Takeuchi O., Mikamo-Satoh E., Hirai R., Kawai T., Matsushita K., et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 205 July 7 (7) (2008) 1601-1610
82. Kamgang R.K., Ramos I., Rodrigues Duarte L., Ghielmetti M., Freudenberg M., Dahinden C., et al. Using distinct molecular signatures of human monocytes and dendritic cells to predict adjuvant activity and pyrogenicity of TLR agonists. Med Microbiol Immunol 197 Dec (4) (2008) 369-379
83. Ahonen C.L., Wasiuk A., Fuse S., Turk M.J., Ernstoff M.S., Suriawinata A.A., et al. Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood 111 March 15 (6) (2008) 3116-3125